The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations

Life Sciences, Molecular Biology, Oncology +12

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome Translocation

Yoshihide Tsujimoto, L R Finger, Jorge J. Yunis et al. · Science · 1984 · 1.8K citations

Life Sciences, Genetics, Oncology +17

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

Mark F. van Delft, Andrew H. Wei, Kylie D. Mason et al. · Cancer Cell · 2006 · 1.2K citations · Full text

Life Sciences, Cell Biology, Pharmacology +10